Last 7 days
-37.5%
Last 30 days
-28.2%
Last 90 days
13.6%
Trailing 12 Months
-62.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 125.3B | 26.3B | -2.75% | 3.76% | 19.12 | 4.76 | 1.32% | 11.18% |
GILD | 99.6B | 27.3B | -8.96% | 41.01% | 21.68 | 3.65 | -0.09% | -26.23% |
MRNA | 58.4B | 19.3B | -12.76% | 1.00% | 6.99 | 3.03 | 4.29% | -31.47% |
BIIB | 38.3B | 10.2B | -9.67% | 32.94% | 12.57 | 3.76 | -7.36% | 95.80% |
MID-CAP | ||||||||
NBIX | 9.1B | 1.5B | -9.09% | 3.35% | 58.87 | 6.11 | 31.34% | 72.43% |
DNLI | 3.2B | 108.5M | -21.10% | -19.55% | -9.78 | 29.38 | 122.90% | -12.19% |
BEAM | 2.5B | 60.9M | -18.47% | -36.46% | -8.76 | 41.55 | 17.51% | 22.00% |
BBIO | 2.1B | 107.9M | 22.95% | 67.45% | -4.29 | 19.27 | 54.84% | 17.36% |
SMALL-CAP | ||||||||
RCUS | 1.2B | 112.0M | -14.86% | -46.41% | -4.63 | 11.04 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -22.18% | 24.65% | -7.11 | 158.97 | 131.81% | -45.39% |
FATE | 541.9M | 96.3M | -12.99% | -82.24% | -1.92 | 5.63 | 72.44% | -32.79% |
NVAX | 513.7M | 2.0B | -39.67% | -92.01% | -0.78 | 0.26 | 72.89% | 62.27% |
SGMO | 355.3M | 111.3M | -30.55% | -58.78% | -1.85 | 3.19 | 0.54% | -7.86% |
VXRT | 101.4M | 159.0K | -16.47% | -82.96% | -0.97 | 637.62 | -86.46% | -64.56% |
IBIO | 25.1M | - | 94.03% | -77.12% | -0.31 | 3.21 | 0.51% | -185.61% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -4.4% | 118,566,000 | 124,063,000 | 122,008,000 | 122,742,000 | 129,071,000 |
S&GA Expenses | -2.0% | 106,256,000 | 108,442,000 | 115,068,000 | 117,369,000 | 124,399,000 |
R&D Expenses | -2.7% | 5,804,000 | 5,968,000 | 6,516,000 | 7,365,000 | 10,420,000 |
Costs and Expenses | -10.1% | 153,906,000 | 171,229,000 | 187,194,000 | 189,702,000 | 208,109,000 |
EBITDA | 58.1% | -12,640,000 | -30,149,000 | -64,055,000 | -76,139,000 | - |
EBITDA Margin | 58.8% | -0.10 | -0.25 | -0.52 | -0.59 | - |
Earnings Before Taxes | 53.5% | -35,247,000 | -75,720,000 | -93,458,000 | -96,734,000 | -109,074,000 |
EBT Margin | 20.3% | -0.61 | -0.77 | -0.79 | -0.85 | - |
Interest Expenses | 1.2% | 30,200,000 | 29,839,000 | 29,541,000 | 29,772,000 | 30,035,000 |
Net Income | 37.6% | -65,916,000 | -105,671,000 | -118,888,000 | -95,070,000 | -104,000,000 |
Net Income Margin | 12.6% | -0.85 | -0.97 | -0.77 | -0.81 | - |
Free Cahsflow | 21.0% | -26,887,000 | -34,033,000 | -28,273,000 | -41,513,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 0.6% | 396 | 393 | 406 | 424 | 455 |
Current Assets | 14.5% | 82.00 | 72.00 | 77.00 | 80.00 | 102 |
Cash Equivalents | 81.4% | 38.00 | 21.00 | 23.00 | 32.00 | 46.00 |
Inventory | -16.4% | 13.00 | 15.00 | 15.00 | 15.00 | 19.00 |
Net PPE | -7.9% | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 |
Current Liabilities | -9.7% | 38.00 | 42.00 | 41.00 | 46.00 | 54.00 |
Long Term Debt | - | 151 | - | - | - | - |
Shareholder's Equity | 23.6% | 94.00 | 76.00 | 88.00 | 128 | 151 |
Retained Earnings | 2.0% | -936 | -955 | -941 | -894 | -870 |
Additional Paid-In Capital | 0.0% | 1,030 | 1,030 | 1,029 | 1,024 | 1,023 |
Accumulated Depreciation | - | 35.00 | - | - | - | - |
Shares Outstanding | 44.7% | 24.00 | 17.00 | 13.00 | - | - |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 21.8% | -20.92 | -26.75 | -33.92 | -28.10 | -41.35 |
Share Based Compensation | -17.1% | 1.00 | 2.00 | 2.00 | 3.00 | 3.00 |
Cashflow From Investing | 47.7% | -0.14 | -0.26 | -0.11 | -0.18 | 74.00 |
Cashflow From Financing | - | -69.65 | - | - | - | - |
100%
100%
91.5%
Y-axis is the maximum loss one would have experienced if Acorda Therapeutics was unfortunately bought at previous high price.
-43.3%
-54.7%
-66.6%
-50.7%
FIve years rolling returns for Acorda Therapeutics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-06 | Rockefeller Capital Management L.P. | new | - | - | - | -% |
2023-02-16 | IMA Wealth, Inc. | unchanged | - | 13.00 | 13.00 | -% |
2023-02-15 | Virtu Financial LLC | sold off | -100 | -6,000 | - | -% |
2023-02-14 | Royal Bank of Canada | reduced | -4.15 | - | - | -% |
2023-02-14 | CANYON CAPITAL ADVISORS LLC | sold off | -100 | -357,000 | - | -% |
2023-02-14 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | reduced | -24.58 | 28,810 | 58,810 | -% |
2023-02-14 | PRUDENTIAL FINANCIAL INC | reduced | -47.84 | 6,074 | 24,074 | -% |
2023-02-14 | TWO SIGMA ADVISERS, LP | added | 1.35 | 7,501 | 11,501 | -% |
2023-02-14 | Verition Fund Management LLC | reduced | -50.00 | 2,459 | 10,459 | -% |
2023-02-14 | TWO SIGMA SECURITIES, LLC | added | 554 | 107,748 | 114,748 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Mar 10, 2023 | davidson kempner capital management lp | 0.21% | 51,189 | SC 13D/A | |
Feb 14, 2023 | canyon capital advisors llc | 0.00% | 0 | SC 13G/A | |
Feb 13, 2023 | renaissance technologies llc | 3.57% | 868,892 | SC 13G/A | |
Jan 23, 2023 | davidson kempner capital management lp | 0.24% | 59,129 | SC 13D/A | |
Jun 10, 2022 | soros fund management llc | 0% | 0 | SC 13G | |
Jun 10, 2022 | davidson kempner capital management lp | 0.28% | 68,229 | SC 13D | |
Feb 14, 2022 | point72 asset management, l.p. | 4.1% | 464,276 | SC 13G/A | |
Feb 14, 2022 | ubs oconnor llc | 0% | 0 | SC 13G/A | |
Feb 14, 2022 | canyon capital advisors llc | 5.79% | 649,031 | SC 13G/A | |
Feb 11, 2022 | renaissance technologies llc | 6.38% | 714,156 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 1.69 170.31% | 1.79 186.31% | 2.39 282.28% | 3.58 472.62% | 4.28 584.58% |
Current Inflation | 1.63 160.72% | 1.72 175.11% | 2.29 266.28% | 3.38 440.63% | 4.02 542.99% |
Very High Inflation | 1.55 147.92% | 1.63 160.72% | 2.15 243.89% | 3.13 400.64% | 3.70 491.81% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 15, 2023 | 10-K | Annual Report | |
Mar 10, 2023 | SC 13D/A | 13D - Major Acquisition | |
Mar 09, 2023 | 8-K | Current Report | |
Feb 15, 2023 | 8-K | Current Report | |
Feb 14, 2023 | SC 13G/A | Major Ownership Report | |
Feb 13, 2023 | SC 13G/A | Major Ownership Report | |
Jan 23, 2023 | SC 13D/A | 13D - Major Acquisition | |
Jan 05, 2023 | 8-K | Current Report | |
Jan 04, 2023 | 4 | Insider Trading | |
Dec 23, 2022 | 8-K | Current Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2022-09-03 | Sabella Lauren M | sold (taxes) | -601 | 0.398 | -1,511 | chief operating officer |
2022-09-03 | Clem Kerry M | sold (taxes) | -601 | 0.398 | -1,511 | chief commercial officer |
2022-03-17 | COHEN RON | sold | -3,894 | 1.7014 | -2,289 | president and ceo |
2021-09-03 | COHEN RON | sold (taxes) | -17,257 | 4.38 | -3,940 | president and ceo |
2021-09-03 | Morales Robert | sold (taxes) | -1,962 | 4.38 | -448 | interim pao & pfo |
2021-09-03 | Sabella Lauren M | sold (taxes) | -6,618 | 4.38 | -1,511 | chief commercial officer |
2021-03-03 | Sabella Lauren M | acquired | - | - | 11,125 | chief commercial officer |
2021-03-03 | BLANK BURKHARD | acquired | - | - | 11,125 | cmo and head of r&d |
2021-03-03 | COHEN RON | acquired | - | - | 29,000 | president and ceo |
2020-12-01 | LAWRENCE DAVID | sold (taxes) | -737 | 0.6464 | -1,141 | chief, bus. ops & pao |
Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | |
Revenues: | ||
Total net revenues | $ 118,566 | $ 129,071 |
Costs and expenses: | ||
Cost of sales | 30,332 | 40,787 |
Research and development | 5,804 | 10,420 |
Selling, general and administrative | 106,256 | 124,399 |
Amortization of intangible assets | 30,764 | 30,764 |
Changes in fair value of derivative liability | (37) | (1,156) |
Changes in fair value of acquired contingent consideration | (6,659) | 2,895 |
Other operating income | (12,554) | |
Total operating expenses | 153,906 | 208,109 |
Operating loss | (35,340) | (79,038) |
Other income (expense), net: | ||
Interest and amortization of debt discount expense | (30,200) | (30,035) |
Interest income | 1,909 | 5 |
Realized Gain (Loss) on FX Currency | (8) | |
Gain on extinguishment of debt | 27,142 | |
Other income (expense) | 1,250 | (6) |
Total other income (expense), net | 93 | (30,036) |
Loss before taxes | (35,247) | (109,074) |
Benefit from (Provision for) income taxes | (30,669) | 5,120 |
Net loss | $ (65,916) | $ (103,954) |
Net loss per share—basic | $ (3.34) | $ (9.79) |
Net loss per share—diluted | $ (3.34) | $ (9.79) |
Weighted average common shares outstanding used in computing net loss per share—basic | 19,707 | 10,621 |
Weighted average common shares outstanding used in computing net loss per share—diluted | 19,707 | 10,621 |
Net Product Revenues | ||
Revenues: | ||
Total net revenues | $ 103,845 | $ 114,189 |
Royalty Revenues | ||
Revenues: | ||
Total net revenues | 14,221 | $ 14,882 |
License Revenue | ||
Revenues: | ||
Total net revenues | $ 500 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 37,536 | $ 45,634 |
Restricted cash | 6,884 | 13,400 |
Trade accounts receivable, net of allowances of $842 and $1,012, as of December 31, 2022 and 2021, respectively | 13,866 | 17,002 |
Prepaid expenses | 4,312 | 6,574 |
Inventory, net | 12,752 | 18,548 |
Other current assets | 6,765 | 999 |
Total current assets | 82,115 | 102,157 |
Property and equipment, net of accumulated depreciation | 2,603 | 4,382 |
Intangible assets, net of accumulated amortization | 305,087 | 335,980 |
Right of use asset, net of accumulated amortization | 5,287 | 6,751 |
Restricted cash | 255 | 6,189 |
Other assets | 248 | 11 |
Total assets | 395,595 | 455,470 |
Current liabilities: | ||
Accounts payable | 9,809 | 10,845 |
Accrued expenses and other current liabilities | 23,680 | 28,605 |
Current portion of liability related to sale of future royalties | 4,460 | |
Current portion of lease liability | 1,545 | 8,186 |
Current portion of acquired contingent consideration | 2,532 | 1,929 |
Deferred revenue | 384 | |
Total current liabilities | 37,950 | 54,025 |
Convertible senior notes | 167,031 | 151,025 |
Derivative liability | 0 | 37 |
Non-current portion of acquired contingent consideration | 38,668 | 47,671 |
Non-current portion of loans payable | 27,645 | |
Deferred tax liability | 44,202 | 13,930 |
Non-current portion of lease liability | 4,341 | 4,086 |
Other non-current liabilities | 9,781 | 5,914 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value per share. Authorized 1,000,000 shares at December 31, 2022 and 2021; no shares issued as of December 31, 2022 and 2021 | ||
Common stock, $0.001 par value per share. Authorized 61,666,666 shares at December 31, 2022 and 2021; issued 24,343,239 and 13,249,802 shares, including those held in treasury, as of December 31, 2022 and 2021, respectively | 24 | 13 |
Treasury stock at cost (5,543 shares at December 31, 2022 and December 31, 2021) | (638) | (638) |
Additional paid-in capital | 1,029,881 | 1,023,136 |
Accumulated deficit | (936,273) | (870,357) |
Accumulated other comprehensive loss | 628 | (1,017) |
Total stockholders’ equity | 93,622 | 151,137 |
Total liabilities and stockholders’ equity | $ 395,595 | $ 455,470 |